Trade GlaxoSmithKline PLC - GSKl CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.042
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment£1,000.00Overnight funding adjustmentCharges from full value of position-0.021268 %(-£4.25)Trade size with leverage ~ £20,000.00Money from leverage ~ $£19,000.00Go to platform: -0.02127%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment£1,000.00Overnight funding adjustmentCharges from full value of position-0.00065 %(-£0.13)Trade size with leverage ~ £20,000.00Money from leverage ~ $£19,000.00Go to platform: -0.00065%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: GBP
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: Great Britain
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: £1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021268 %
  (-£4.25)

• Margin. Your investment: £1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00065 %
  (-£0.13)

Key Stats

• Prev. Close: 18.4165
• Open: 18.2417
• 1-Year Change: 23.97%
• Day's Range: 18.2417 - 18.4615

Trade GlaxoSmithKline PLC - GSKl

GlaxoSmithKline PLC - GSK CFD

GlaxoSmithKline (GSK) is a global healthcare company focussed in pharmaceuticals, vaccine development and consumer healthcare products. 

The company began as an apothecary shop in London in 1715. Today, GlaxoSmithKline is headquartered in Brentford, England, with regional offices in the US and Singapore. GlaxoSmithKline’s primary listing is on the London Stock Exchange under the ticker symbol ‘GSK’. The GSK stock price in the form of  American depositary shares is listed on the New York Stock Exchange.   

GlaxoSmithKline’s pharmaceutical business covers a broad portfolio of medicines in respiratory, HIV, immuno-inflammation and oncology. The company has a leadership position in respiratory disease medicines. GlaxoSmithKline’s HIV business is managed through its unit ViiV Healthcare, with Pfizer and Shionogi as minority shareholders. 

In addition to respiratory and HIV treatments, the company has a portfolio of pharmaceutical products for the treatment of conditions such as lupus, urology and anti-infectives. 

Its Established Products Portfolio (EPP) includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology. These products are an important part of our Emerging Markets business.

GlaxoSmithKline is actively researching the World Health Organisation’s three priority diseases - HIV/AIDS, tuberculosis and malaria.

GlaxoSmithKline is also one of the world’s largest vaccine companies with a portfolio of more than 20 vaccines. The company has 12 vaccine manufacturing sites around the world. One of its four global R&D centres is dedicated to mRNA technology.

GlaxoSmithKline’s consumer healthcare business has portfolio of brands that include Sensodyne, Parodontax, Polident, Advil, Voltaire, Panadol, Striven, Theraflu and Centrum across oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, mineral and supplements segments. GlaxoSmithKline is set to spin-off its consumer healthcare business into an independent company under the name ‘Haleon’.’

The company pays dividends on a quarterly basis, in July, October, January and April.
Follow the GlaxoSmithKline stock price live at Capital.com today.